The intrinsic apoptotic signaling pathway in gastric adenocarcinomas of Brazilian patients: Immunoexpression of the Bcl-2 family (Bcl-2, Bcl-x, Bak, Bax, Bad) determined by tissue microarray analysis

Molecular Medicine Reports

Volumn 3, Issue 2, 2010, Pages 261-267

  Mesías Barrezueta, Luis Fernando ^a   Fujiyama Oshima, Celina Tizuko ^a   Lima, Oliveira Flávio ^a   De Oliveira Costa, Henrique ^a   Gomes, Simão Thiago ^a   Neto, Ricardo Artigiani ^a   Marcello Fabiano De Franco, ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Apoptosis; Family Bcl 2; Gastric cancer; Immunohisto chemistry; Prognosis

Indexed keywords

CASPASE 3; KI 67 ANTIGEN; PARAFFIN; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; BRAZIL; CANCER SIZE; CANCER SURVIVAL; CANCER TISSUE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STAINING; STOMACH ADENOCARCINOMA; STOMACH CARCINOMA; STOMACH MUCOSA; TISSUE MICROARRAY;

EID: 77950846702     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr-00000249     Document Type: Article

References (39)

1. Magalhães LP, Oshima CT, Souza LG, Lima JM, Carvalho L and Forones NM: Weight: educational achievement, basic sanitation, alcoholism, smoking and eating habit in patients with gastric cancer. Arq Gastroenterol 45: 111-116, 2008.
2. Lauren P: The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at histo-clinical classification. Acta Pathol Microbiol Scand 64: 31-49, 1965.
3. Ladeira M, Salvador D and Rodriguez M: Biopatologia do helicobacter pylori. Journal Brasileiro de Patologia e Medicina Laboratorial 39: 335-342, 2003.
4. Zhang C, Yamada N, Wu WL, Wen M, Matsuhisa T and Matsukura N: Helicobacter pylori infection, glandular atrophy and intestinal metaplasia in superficial gastritis, gastric erosion, erosive gastritis, gastric ulcer and early gastric cancer. World J Gastroenterol 11: 791-796, 2005.
5. Correa P: Human gastric carcinogenesis: a multistep and multifactorial process - First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 52: 6735-6740, 1992.
6. Hamilton SR and LA Aaltonen (eds): World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Digestive System. IARC Press, Lyon, pp1429-1433, 2003.
7. Hengartner M: The biochemistry of apoptosis. Nature 407: 770-776, 2000.
8. Saraste A and Pulkki K: Morphologic and biochemical hallmarks of apoptosis. Cardiovasc Res 45: 528-537, 2000.
9. Reed JC: Dysregulation of apoptosis in cancer. J Clin Oncol 17: 2941-2953, 1999.
10. Reed JC: Bcl-2 family proteins. Oncogene 17: 3225-3236, 1998.
11. Bratton SB, MacFarlane M, Cain K and Cohen GM: Protein complexes activate distinct caspase cascades in death receptor and stress-induced apoptosis. Exp Cell Res 256: 27-33, 2000.
12. Denault JB and Salvesen GS: Caspases: keys in the ignition of cell death. Chem Rev 102: 4489-4500, 2002.
13. Coultas L and Strasser A: The role of the Bcl-2 protein family in cancer. Semin Cancer Biol 13: 115-123, 2003.
14. Cory S and Adams JM: The Bcl2 family: regulators of the cellular life-or- death switch. Nat Rev Cancer 2: 647-656, 2002.
15. Borner C: The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol 39: 615-647, 2003.
16. Susin S, Lorenzo H, Zamzami N, et al: Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397: 441-446, 1999.
17. Koshida Y, Saegusa M and Okayasu I: Apoptosis, cell proliferation and expression of Bcl-2 and Bax in gastric carcinomas: immunohistochemical and clinicopathological study. Br J Cancer 75: 367-373, 1997.
18. Bir F, Calli-Demirkan N, Tufan AC , Akbulut M and Satiroglu-Tufan NL: Apoptotic cell death and its relationship to gastric carcinogenesis. World J Gastroenterol 13: 3183-3188, 2007.
19. Reed JC, Miyashita T, Takayama S, Wang HG, Sato T, Krajewski S, Aimé-Sempé C, Bodrug S, Kitada S and Hanada M: BCL -2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 60: 23-32, 1996.
20. Sobin LH and Wittekind C (eds): International Union against Cancer (UICC) TNM classification of malignant tumours. 5th edition. Wiley-Liss, New York, 1997.
21. Krajewska M, Krawesky S, Epstein J, et al: Immunohistochemical analysis of Bcl-2, bax, bcl-x and mcl-1 expression in prostate cancers. Am J Pathol 148: 1567-1576, 1996.
22. Fernebro E, Dictor M, Bendahl PO, Fernö M and Nilbert M: Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer. Arch Pathol Lab Med 126: 702-705, 2002.
23. Lee DS, Kang SB, Baek JT, Nam SW, Lee KM, Ahn BM, Lee EH, Han SW and Chung IS: Immunohistochemical expression of bcl-2, bcl-xl, bax, p53 proteins in gastric adenoma and adenocarcinoma. Korean J Gastroenterol 45: 394-400, 2005.
24. Forones NM, Carvalho AP, Giannotti-Filho O, Lourenço LG and Oshima CT: Cell proliferation and apoptosis in gastric cancer and intestinal metaplasia. Arq Gastroenterol 42: 30-34, 2005.
25. Müller W, Schneiders A, Hommel G and Gabbert HE: Prognostic value of Bcl-2 expression in gastric cancer. Anticancer Res 18: 4699-4704, 1998.
26. et al: Immunohistochemical analysis of in vivo patterns of Bcl-x expression. Cancer Res 54: 5501-5507, 1994.
27. Krajewska M, Fenoglio-Preiser C, Krajewsky S, et al: Immunohistochemical analysis of Bcl-2 family protein in adenocarcinoma of the stomach. Am J Pathol 49: 1449-1457, 1996.
28. Vairo G, Innes KM and Adams JM: Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. Oncogene 13: 1511-1519, 1996.
29. Schmitt E, Beauchemin M and Bertand R: Nuclear colocalization and interation between bcl-xL and cdk1 (cdc2) during G2/M cell-cycle checkpoint. Oncogene 26: 5851-5865, 2007.
30. Holinger EP, Chittenden T and Lutz RJ: Bak BH3 peptides antagonize Bcl-xl function and induce apoptosis through cytochrome c-independent activation of caspases. J Biol Chem 274: 13298-13304, 1999.
31. Hinds MG, Smits C, Fredericks-Short R, Risk JM, Bailey M, Huang DC and Day CL : Bim, Bad and Bmf: intrinsically unstructured BH3-only proteins that undergo a localized conformational change upon binding to prosurvival Bcl-2 targets. Cell Death Differ 14: 128-136, 2007.
32. Krajewska M, Moss SF, Krajewski S, Song K, Holt PR and Reed JC: Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res 56: 2422-2427, 1996.
33. Estrov Z, Thall PF, Talpaz M, et al: Caspase 2 and caspase-3 protein levels as predictors of survival in acute myelogenous leukemia. Blood 92: 3090-3097, 1998.
34. Anagnostopoulos GK, Stefanou D, Arkoumani E, et al: Bax and Bcl-2 protein expression in gastric precancerous lesions: immunohistochemical study. J Gastroenterol Hepatol 20: 1674-1678, 2005.
35. Lee KE, Lee HJ, Kim YH, et al: Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer. Jpn J Clin Oncol 33: 173-179, 2003.
36. Sot B, Freund SM and Fersht AR : Comparative biophysical characterization of p53 with the pro-apoptotic BAK and the anti-apoptotic BCL -xl. J Biol Chem 282: 29193-29200, 2007.
37. Kodera Y, Yamamura Y, Shimizu Y, et al: The number of metastatic lymph nodes: a promising prognostic determinant for gastric carcinoma in the latest edition of the TNM classification. J Am Coll Surg 187: 597-603, 1998.
38. Oshima FTC: Helicobacter pylori and expression of AgNOR s, Ki-67, c-erbB-2 and p53 in gastric adenocarcinoma (PhD thesis). Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo, 1999.
39. Oshima CT, Iriya K and Forones NM: Ki-67 as a prognostic marker in colorectal cancer but not in gastric cancer. Neoplasma 52: 420-424, 2005.